Immunome CEO receives new stock options and RSUs

Immunome Inc. granted equity awards to President and CEO Clay B. Siegall on July 23, 2026.

Rhea-AI Filing Summary

Immunome Inc. granted equity awards to President and CEO Clay B. Siegall on July 23, 2026. He received 180,000 RSUs, with 25% vesting on each anniversary of the grant date, and 360,000 stock options with a $22.01 exercise price, 25% vesting on July 23, 2027 and the remainder in equal monthly installments thereafter, all subject to continued service. Following the RSU grant, he directly holds 870,704 common shares, in addition to the newly granted options.

Insider Trade Summary

Grant/Award: 540,000 shares

Grant/Award 2 txns

Insider SIEGALL CLAY B

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy) F2	360,000	$0.00	$0.00
Grant/Award	Common Stock F1	180,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 360,000 contracts (Direct); Common Stock — 870,704 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
2. F2. 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Key Figures

RSUs granted: 180,000 shares Stock options granted: 360,000 options Option exercise price: $22.01 per share +2 more

5 metrics

RSUs granted 180,000 shares Restricted stock units granted to President and CEO on July 23, 2026

Stock options granted 360,000 options Employee stock options granted on July 23, 2026

Option exercise price $22.01 per share Exercise price of the 360,000 stock options granted to the CEO

Option expiration date July 22, 2036 Expiration date of the employee stock options granted

Shares held after grant 870,704 shares Direct common stock holdings of the CEO after the RSU grant

Key Terms

restricted stock units ("RSUs"), contingent right, continuous service, Employee Stock Option (right to buy)

4 terms

restricted stock units ("RSUs") financial

"Represents the number of shares of the Issuer's common stock underlying restricted stock units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents the contingent right to receive one share of Common Stock upon settlement."

continuous service financial

"subject to the Reporting Person's continuous service through each such vesting date."

Employee Stock Option (right to buy) financial

"security title: Employee Stock Option (right to buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Immunome (IMNM) grant to its CEO in this Form 4?

Immunome granted CEO Clay B. Siegall 180,000 RSUs and 360,000 stock options on July 23, 2026. The RSUs convert one-for-one into common stock upon vesting, while the options carry a $22.01 exercise price and long-dated expiration.

How do the 180,000 RSUs for Immunome (IMNM) CEO vest over time?

The 180,000 RSUs vest and settle into common stock in four equal annual installments of 25%. Each 25% tranche vests on the anniversary of the July 23, 2026 grant date, conditioned on the CEO’s continuous service through each vesting date.

What are the key terms of the 360,000 stock options granted by Immunome (IMNM)?

The CEO received 360,000 employee stock options with a $22.01 exercise price expiring on July 22, 2036. 25% vest on July 23, 2027, and the remaining options vest in equal monthly installments thereafter, subject to continued service.

How many Immunome (IMNM) common shares does the CEO own after these grants?

After the RSU grant, Clay B. Siegall directly holds 870,704 shares of Immunome common stock. This figure reflects his reported direct non-derivative holdings and excludes the 360,000 newly granted options, which are reported separately as derivative securities.

Were the Immunome (IMNM) CEO’s reported awards made under a Rule 10b5-1 trading plan?

The awards were reported as grants, and the Rule 10b5-1 trading plan checkbox was not marked as applicable. This indicates the reported transactions were not affirmatively designated as occurring under a pre-arranged Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/27/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SIEGALL CLAY B

(Last) (First) (Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/23/2026		A		180,000(1)	A	$0	870,704	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$22.01	07/23/2026		A		360,000		(2)	07/22/2036	Common Stock	360,000	$0	360,000	D

Explanation of Responses:

1. Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.

2. 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.

	/s/ Sandra Stoneman, Attorney-in-Fact	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)